GOSS May 2024 1.500 put
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.4000 |
| Ask | 1.0500 |
| Strike | 1.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
Business WireGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
SAN DIEGO, May 03, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (T
Simply Wall St.Gossamer Bio Decline Means Insider Profits Down To US$17k
Insiders who bought Gossamer Bio, Inc. ( NASDAQ:GOSS ) stock lover the last 12 months are probably not as affected by...
Insider Monkey13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
